Adam Hargreaves’ Post

Funding Update - What's happening in USA? - Biotech companies are getting massive funding #ObsidianTherapeutics secured a whopping $161M in a Series C financing round led by new investor Wellington Management. The Cambridge-based biotech company is advancing engineered cell and gene therapies to tackle cancer. #Flip, a social commerce startup, raised $144M in funding led by Streamlined Ventures, with a significant investment from AppLovin. Their innovative marketplace for video reviews is making waves in Los Angeles and beyond. #AlteromeTherapeutics scored $132M in a Series B round led by Goldman Sachs Alternatives. Their machine learning platform Kraken is driving the development of promising oncology therapies. #DiagonalTherapeutics emerged with $128M in a Series A round co-led by BVF Partners and Atlas Venture. They're on a mission to combat hereditary hemorrhagic telangiectasia, a challenging bleeding disorder. #Aerospike closed a hefty $109M investment led by Sumeru Equity Partners. The demand for their real-time NoSQL database management system is skyrocketing with the rise of AI applications. In addition to these, notable rounds include: - #AlsymEnergy: $78M led by Tata Limited and General Catalyst - #SiMa.ai: $70M led by Maverick Capital - #Torus: $67M led by Origin Ventures - #BinxHealth: $65M led by Hildred Capital - #Homebase: $60M led by L Catterton Growth And a special shoutout to Paris-based #Pigment, a business forecasting platform, which raised an impressive $145M in venture funding! Follow me to see more updates like this. #StartupFunding #VentureCapital #InnovationLeadership

Another day, another breakthrough with over $400M being raised for startups in the valley. Yesterday's funding landscape was dominated by groundbreaking advancements in healthcare and environmental technology. Notable Deals: •  Freenome successfully secured $254 million in its latest funding round, boosting its total capital to $1.4 billion. The company is at the forefront of early cancer detection, developing a series of blood tests through its innovative multiomics platform. • Kairos Aerospace, known for its methane leak detection technology raised $52 million. • Scribe, a service dedicated to the documentation and dissemination of business processes, has achieved $25 million in Series B funding. ------------------------------------------------------------------------------------ This year biotech is poised to steal the spotlight, with investor enthusiasm expected to surge in response to emerging developments in cancer vaccines. Ensure you're always in the loop - subscribe to our newsletter for the latest updates in deals and events in the valley.

On Point: Innovation & Startups Bryan Dechairo on the challenges commercializing high-tech, low-cost products. - We associate ease of use and low-cost with low-tech. It doesn’t work. Throw it out. Try another one. No need to call the help desk. - But what happens if you raise the stakes? You prescreen yourself with an at-home test for cancer. That test better work. - Extremely sophisticated diagnostics platform. Low-cost, user-friendly products that work every time. Those are the stakes at Sherlock Biosciences. - Watch this video https://bit.ly/3T66uzC Watch the full episode https://bit.ly/482uIPl MassMEDIC

Why biotech spinouts are in the North East’s genes. 🔎🇬🇧 Ten years ago, I slipped in through a side door to the office block that rings Times Square in Newcastle, next to the Life Science Centre near the city’s central station, and spoke to Jonathan O’Halloran, the co-founder and chief scientific officer of QuantuMDx, a Newcastle-based biotech startup. I was there to write a story on QuantuMDx’s killer product, a Star Trek-like tricorder that would take blood or saliva samples and provide instantaneous results to diagnostic tests. The Q-POC, as it was called, was a revolutionary technology. ➡️ https://lnkd.in/esZE9i6K 🔗 #biotech #startup #spinouts #technology #northeast #genes #UKtech

📢 Founder Stories University Edition is a collection of fireside chats with leading academic founders backed by the AlbionVC team. Having invested in over 30 university spinouts from the leading UK universities, the series highlights personal stories of those who made the leap from academia to entrepreneurship.  In this episode of our founder stories, Professor Amit Nathwani, CEO NovalGen and a leading global mind in gene therapy research, walks Simon Goldman, Partner AlbionVC, through his academic and business career and what still drives him today. Amit reflects on his journey from academia to entrepreneurship, how his early years as a clinician have influenced his licensing deals with big pharmaceutical companies and later his two spinout companies. “The UCL Technology Fund for me has enabled two of my spinout companies. It’s been extremely important for us and UCL as an environment. I think for me it has been crucial because I could not have done what we've been able to do otherwise.” said Prof. Amit Nathwani, CEO, NovalGen     Watch the full story here: https://lnkd.in/eh2zsEFY UCL Business Ltd #biotech #lifesciences #immunotherapy #cancerresearch #BiotechInnovation #medicalbreakthroughs #tech #uktech #founders #startups #entrepreneurs #venturecapital #founderstories

Once heralded as one of the world's hottest startups, personal genetics testing company 23andMe has recently garnered attention for its notable decline in valuation and data breach. Long at the center of 23andMe's success - and now struggles - is co-founder and CEO Anne Wojcicki. Less frequently mentioned is co-founder, biologist and entrepreneur Linda Avey. Even less mentioned and sometimes omitted is co-founder and #engineer Paul Cusenza. Learn more about the founding of 23andMe in my latest Forbes column. #innovation #23andMe #founderstory #startup #funding University of Michigan University of Michigan College of Engineering Mechanical Engineering Department - University of Michigan Harvard University Harvard Business School

Swedish startup’s $26 million Series A funding marks a turning point in cellular communication mapping Moleculent, a Stockholm-based company focused on advancing the spatial mapping of cell-cell communication, has secured a significant milestone with the closing of its oversubscribed $26 million Series A financing round. This round was co-led by ARCH Venture Partners and Eir Ventures, with participation from existing investors. The funding will support Moleculent’s innovative functional biology platform, which enables the detection and profiling of cell-cell interactions directly within tissue environments. Moleculent announced key appointments to its leadership team. Patrick A. Weiss from ARCH Venture Partners has been appointed Chairman of the Board, while Sean Kendall from ARCH and Magnus Persson from Eir Ventures have joined the company’s Board of Directors. https://lnkd.in/d6v87T7R #nordicmade #sweden #funding #deeptech #lifesciences #biotech #healthtech #startups #trending

As we kick off the new year with optimism and innovation, let's dive into January's funding fireworks in this month's #FUNDLAB 🚀 💸 Remix Therapeutics closed a $60M financing round to advance its REM-422 pipeline of small molecule therapies. 💸 Moonwalk Biosciences launched $57M in seed and Series A financing to advance the company's epigenetic discovery platform. 💸 Elephas announced a substantial $55M in Series C funding, bringing the total raised by Elephas to $116.5 million. 💸 S2 Genomics raised $16M in Series A funding, pushing the boundaries of sample preparation for genomic research. 💸 IMU Biosciences closed a $14.7M Series A financing round, marking a significant step forward in their innovative endeavours. 💸 CRISPR QC secured $10M in Series A financing round led by Xcellerant Ventures. 💸 Circular Genomics raised $8.3M in Series A financing round led by Mountain Group Partners. 💸 Via Scientific, Inc., a multiomic informatics startup, raised $5M in seed funding led by G20 Ventures and Innospark Ventures. What's your take on these investments? Share your thoughts below! ⬇️ Gilbert Meher #fundingnews #lifesciences #startupfunding #lifesciencesindustry #cancerresearch

#fundingalert 💼Company: En Carta Diagnostics 💰Funding: €1.5 Million ⚡Round: Pre-Seed 👥Investors: CentraleSupélec Venture Diagnostics that enhance patient care, regardless of location. En Carta Diagnostics is a synthetic-biology biotech company that employs patented #technologies to decentralise highly dependable molecular diagnostic solutions. The proceeds will be utilised by En Carta to create a diagnostic device that is capable of independently detecting Lyme disease within minutes. Additionally, the funding will facilitate the #development of a robust ecosystem and the execution of its go-to-market strategy. Guillaume Horréard, Cédric Curtil, Margot Karlikow, PhD Read more - https://lnkd.in/g75Khj7x To share your startup story write us on - contact@startuprise.co.uk #EnCartaDiagnostics #moleculardiagnostic #biotechcompany #funding #fundingnews #startup #startupnews #startuprise

Generally a selection process for identifying one winner, this year, the Board of Governors, philanthropist Gail Asper, panel judges Itzik Goldwaser, CEO of Yissum, The Hebrew University Tech Transfer Company, Professor Shlomo Magdassi and crowd were inspired by advanced technologies shaping the world and our future. GynTools and Hydro X have been named the winners of the 2024 ASPER-HUJI Innovate Rising Startups of the Year. GynTools, a Jerusalem-based startup, has developed Gyni, an AI-based diagnostic system for vaginitis, addressing a common problem in gynecological care with its rapid and accurate diagnosis capabilities. With worldwide patents and commercialization efforts underway in Israel, Europe, and the USA, GynTools aims to revolutionize women's healthcare. Hydro X, a startup supported by Yissum at The Hebrew University of Jerusalem, is pioneering hydrogen storage and transportation technology, making hydrogen storage safer, more efficient, and cost-effective, thus advancing the hydrogen economy. This technology will change the world in how we view our energy sources. While acknowledging the exceptional efforts of finalists, including IntraGel Therapeutics, COGNIFIBER, and RumaFeed, Yissum expresses anticipation for the transformative impact these startups will have globally. #Innovation #WeAreOne #Awards #BOG2024 Amnon Dekel, PhD | Asper Foundation